Associated Papers
Neo-Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein.
Kumari P et al.
Angewandte Chemie (international Ed. in English), 2026
NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting.
Panda H et al.
Oncogene, 2025
Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project.
Kato T et al.
British Journal of Cancer, 2025
The complexity of tobacco smoke-induced mutagenesis in head and neck cancer.
Torrens L et al.
Nature Genetics, 2025
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition.
Zhang T et al.
Biorxiv : the Preprint Server for Biology, 2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Arun AS et al.
The Pharmacogenomics Journal, 2025
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer.
Eklund EA et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
Targeted gene sequencing and bioinformatics analysis of patients with gallbladder neuroendocrine carcinoma: A case report.
Yang YC et al.
World Journal of Gastrointestinal Oncology, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.
Lui K et al.
International Journal of Molecular Sciences, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Science Advances, 2024
Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.
Deen AJ et al.
Redox Biology, 2024
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.
Shiller M et al.
Frontiers in Oncology, 2024
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM et al.
Cell Reports, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Biorxiv : the Preprint Server for Biology, 2023
Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumors.
Karagiannis D et al.
Biorxiv : the Preprint Server for Biology, 2023
Regulation of Cell Proliferation and Nrf2-Mediated Antioxidant Defense: Conservation of Keap1 Cysteines and Nrf2 Binding Site in the Context of the Evolution of KLHL Family.
Shilovsky GA et al.
Life (basel, Switzerland), 2023
The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation.
Gopal P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
RNA-SSNV: A Reliable Somatic Single Nucleotide Variant Identification Framework for Bulk RNA-Seq Data.
Long Q et al.
Frontiers in Genetics, 2022
NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.
Gong XY et al.
Frontiers in Immunology, 2022
Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer.
Dutta N et al.
Frontiers in Oncology, 2022
Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition.
Ding H et al.
Science Advances, 2021
The conformational and mutational landscape of the ubiquitin-like marker for autophagosome formation in cancer.
Fas BA et al.
Autophagy, 2021
Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
Cheng W et al.
Thoracic Cancer, 2021
KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability.
Wilson CJ et al.
International Journal of Molecular Sciences, 2021
Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway.
Peterson J et al.
Scientific Reports, 2020
KEAP1 Mutations Drive Tumorigenesis by Suppressing SOX9 Ubiquitination and Degradation.
Shao N et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2020
NRF2-Driven KEAP1 Transcription in Human Lung Cancer.
Tian Y et al.
Molecular Cancer Research : Mcr, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ et al.
Genome Medicine, 2020
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Kang T et al.
Breast Cancer Research : Bcr, 2020
Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results.
Olkinuora A et al.
Cancers, 2020
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L et al.
Redox Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Systematic analysis of the intersection of disease mutations with protein modifications.
Simpson CM et al.
Bmc Medical Genomics, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
Cloer EW et al.
Molecular and Cellular Biology, 2018
A catalogue of somatic NRF2 gain-of-function mutations in cancer.
Kerins MJ et al.
Scientific Reports, 2018
KEAP1/NRF2 signaling pathway mutations in cervical cancer.
Chu XY et al.
European Review for Medical and Pharmacological Sciences, 2018
MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer.
Gauthier NP et al.
Nucleic Acids Research, 2016